



Proteomics International

LABORATORIES LTD

ASX Release
14 November 2018

ASX code: PIQ

Proteomics appoints Adelaide Equity Partners and Scintilla Capital as Corporate Advisors

Medical technology company Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ), is pleased to announce it has appointed Adelaide Equity Partners, working in conjunction with Scintilla Capital, as its Corporate Advisors.

Adelaide Equity is an independent investment bank, specialising in the provision of corporate advisory services for small-mid ASX listed companies in the healthcare, natural resource, industrial and technology sectors.

Scintilla Capital is a specialist fund manager focused on high growth microcap ASX listed companies that target the disruptive technologies of tomorrow.

Adelaide Equity and Scintilla Capital will provide services on reasonable commercial terms, which include issuance of options to acquire shares in PIQ as follows:

- 1,250,000 to Adelaide Equity upon PIQ shares achieving a 20 day VWAP of \$0.45, exercisable at \$0.50 cents per option within 3 years of issuance
- 500,000 to Scintilla Capital upon PIQ shares achieving a 20 day VWAP of \$0.45, exercisable at \$0.50 cents per option within 3 years of issuance

Proteomics International believes it is at an important stage of its corporate development with the on-going global rollout of its pioneering predictive test for diabetic kidney disease, PromarkerD, development of new diagnostics tests from its Promarker™ pipeline, and growing revenue from its analytical services.

Adelaide Equity and Scintilla Capital will work together to provide investor relations support and corporate advisory services to Proteomics International to unlock investor value and establish the foundation for further corporate growth.

ENDS

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Dirk van Dissel
[Corporate Advisor & Investor Relations]
Adelaide Equity Partners
T: +61 8 8232 8800
E: dvandissel@adelaideequity.com.au

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) (ASX: PIQ) is a medical technology company at the forefront of predictive diagnostics and bio-analytical services. Proteomics International's business model is centred on the commercialisation of the company's world-leading test for diabetic kidney disease, PromarkerD, whilst using its proprietary Promarker™ technology platform to create a pipeline of novel diagnostic tests, and offset the cash burn from R&D and product development through provision of specialist analytical services.

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com